Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: Systematic review and meta-analysis

American Journal of Gastroenterology

Volumn 106, Issue 12, 2011, Pages 2070-2077

  Ford, Alexander C ^a,b   Khan, Khurram J ^c   Sandborn, William J ^d   Kane, Sunanda V ^e   Moayyedi, Paul ^c  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE;

DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; FOLLOW UP; HUMAN; LETHARGY; META ANALYSIS; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; VOMITING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; HUMANS; MESALAMINE; RECURRENCE; TREATMENT OUTCOME;

EID: 82955225240     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.296     Document Type: Review

References (35)

1. Loft us CG, Loft us Jr EV, Harmsen WS et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Infl amm Bowel Dis 2007; 13: 254-61. (Pubitemid 46465905)
2. Loftus EVJ, Silverstein MD, Sandbornn WJ et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gut 2000; 46: 336-43. (Pubitemid 30313384)
3. Shivananda S, Lennard-Jones J, Logan R et al. Incidence of infl ammatory bowel disease across Europe: is there a diff erence between north and south? Results of the European collaborative study on infl ammatory bowel disease (EC-IBD). Gut 1996; 39: 690-7. (Pubitemid 26426470)
4. Talley NJ, Abreu MT, Achkar J-P et al. An evidence-based systematic review on medical therapies for infl ammatory bowel disease. Am J Gastroenterol 2011; 106 (Suppl 1s): S2-S25.
5. Kappelman MD, Rifas-Shiman SL, Kleinman K et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-9. (Pubitemid 350181588)
6. Ford AC, Bernstein CN, Khan KJ et al. Glucocorticosteroid therapy in infl ammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 590-9.
7. Ford AC, Achkar J-P, Khan KJ et al. Effi cacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 601-16.
8. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis (Review). Cochrane Database Syst Rev 2006; (2): CD00543.
9. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis (Review). Cochrane Database Syst Rev 2006, CD00544.
10. Kane SV, Cohen RD, Aikens JE et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-33. (Pubitemid 32959535)
11. Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-8. (Pubitemid 36951655)
12. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577-85.
13. Das KM, Eastwood MA, Mcmanus JP et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 491-5.
14. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 82-6. (Pubitemid 19032930)
15. Hussain FN, Ajjan RA, Kapur K et al. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001; 15: 53-62. (Pubitemid 32055586)
16. Kamm MA, Sandborn WJ, Gassull M et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75. (Pubitemid 46108735)
17. Lichtenstein GR, Kamm MA, Boddu P et al. Eff ect of once-or twice-daily MMX mesalamine (Spd476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95-102. (Pubitemid 46096842)
18. Lichtenstein GR, Gordon GL, Zakko S et al. Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis-a 6-month placebo-controlled trial. Aliment Pharmacol Ther 2010; 32: 990-9.
19. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Version 5.0.0. http://www.cochrane-handbook.org, 2008.
20. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. (Pubitemid 17189972)
21. Higgins JPT, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-60. (Pubitemid 37088507)
22. Egger M, Davey-Smith G, Schneider hneider M et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34. (Pubitemid 27387172)
23. Dignass AU, Bokemeyer B, Adamek H et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762-9.
24. Hawthorne AB, Stenson R, Gillespie D et al. Once daily Asacol in maintenance therapy for ulcerative colitis: a one-year single-blind randomised trial. Gut 2011; 60 (Suppl 1): A37-8.
25. Kamm MA, Lichtenstein GR, Sandborn WJ et al. Randomised trial of onceor twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008; 57: 893-902. (Pubitemid 351919522)
26. Kane S, Holderman W, Jacques P et al. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Prefer Adherence 2008; 2: 253-8.
27. Kruis W, Jonaitis L, Pokrotniets J et al. Randomised clinical trial: a comparative dose-fi nding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 33: 313-22.
28. Prantera C, Kohn A, Campieri M et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther 2009; 30: 908-18.
29. Sandborn WJ, Korzenik J, Lashner B et al. Once-daily dosing of delayedrelease oral mesalamine (400-mg tablet) is as eff ective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 2010; 138: 1286-96.
30. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 540-9. (Pubitemid 23085797)
31. Pullar T, Birtwell AJ, Wiles PG et al. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther 1988; 44: 540-5. (Pubitemid 19002867)
32. Grosset KA, Bone I, Reid JL et al. Measuring medication adherence in Parkinson's disease: a comparison of methods. J Neurol Neurosurg Psychiatry 2006; 77: 249-51. (Pubitemid 43220854)
33. Kane S, Huo D, Aikens J et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43. (Pubitemid 36126514)
34. Higgins PD, Rubin DT, Kaulback K et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis fl ares. Aliment Pharmacol Ther 2009; 29: 247-57.
35. Kane SV, Robinson A. Review article: understanding adherence to medication in ulcerative colitis-innovative thinking and evolving concepts. Aliment Pharmacol Ther 2010; 32: 1051-8.